Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PALBOCICLIB Cause Product prescribing issue? 103 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 103 reports of Product prescribing issue have been filed in association with PALBOCICLIB (Ibrance). This represents 0.1% of all adverse event reports for PALBOCICLIB.

103
Reports of Product prescribing issue with PALBOCICLIB
0.1%
of all PALBOCICLIB reports
2
Deaths
17
Hospitalizations

How Dangerous Is Product prescribing issue From PALBOCICLIB?

Of the 103 reports, 2 (1.9%) resulted in death, 17 (16.5%) required hospitalization, and 2 (1.9%) were considered life-threatening.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 103 reports have been filed with the FAERS database.

What Other Side Effects Does PALBOCICLIB Cause?

Fatigue (15,190) White blood cell count decreased (11,273) Neoplasm progression (10,885) Death (8,410) Nausea (8,189) Neutropenia (6,423) Alopecia (6,201) Diarrhoea (5,635) Asthenia (3,660) Off label use (3,405)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which PALBOCICLIB Alternatives Have Lower Product prescribing issue Risk?

PALBOCICLIB vs PALIPERIDONE PALBOCICLIB vs PALIVIZUMAB PALBOCICLIB vs PALONOSETRON PALBOCICLIB vs PAMIDRONATE PALBOCICLIB vs PAMIDRONIC ACID

Related Pages

PALBOCICLIB Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue PALBOCICLIB Demographics